Spots Global Cancer Trial Database for Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
Official Title:
Study ID: NCT02520245
Conditions
Interventions
Study Description
Brief Summary: This study has been designed to collect long-term follow-up information for patients who received REGN2810 in other clinical studies and to allow re-treatment for eligible patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope National Medical Center, Duarte, California, United States
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
Washington University School of Medicine Siteman Cancer Center, St. Louis, Missouri, United States
Laura & Isaac Perlmutter Cancer Center, New York, New York, United States
University Hospitals Case Medical Center, Cleveland, Ohio, United States
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Providence Portland Medical Center, Portland, Oregon, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
START South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Contact Details
Name: Clinical Trial Management
Affiliation: Regeneron Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
